Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
Metrics: PDF 535 views | HTML 701 views | ?
Binghao Zhao1, Wenxiong Zhang1, Dongliang Yu1, Jianjun Xu1 and Yiping Wei1
1Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
Wenxiong Zhang, email: email@example.com
Keywords: non-small cell lung cancer, adoptive immunotherapy, meta-analysis
Received: April 25, 2017 Accepted: July 06, 2017 Published: July 19, 2017
Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneity
Of 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included. Compared to the Control therapy (CT) group, the AIT group exhibited better 1-year OS (P = 0.001), 2-year OS (P < 0.001), 3-year OS (P < 0.001), 5-year OS (P = 0.032), 1-year PFS (P < 0.001), and 2-year PFS (P = 0.029). The difference in the ORR (P = 0.293) and DCR (P = 0.123) was not significant between the groups. The subgroup analysis showed that DC/CIK did more benefit to NSCLC patients than LAK and the cycles not associated with AIT efficacy.
AIT can significantly improve the OS and PFS with acceptable toxicity for NSCLC. Nevertheless, further multicenter studies are needed to confirm our conclusion and determine which adoptive immunotherapy is associated with the greatest efficacy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.